Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | IDO1 | P14902 | 3/20 | 0.52 |
| ▸ | NAAA | Q02083 | 1/20 | 0.50 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.49 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | AGXT | P21549 | 1/20 | 0.43 |
| ▸ | APP | P05067 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2658064 | 0.94 | TSHR (0.54) | TSHRIDO1NAAACHRM3LTA4H | |
| SCHEMBL2657770 | 0.93 | TSHR (0.71) | TSHRIDO1NAAACHRM3TDP1 | |
| SCHEMBL3686733 | 0.92 | TSHR (0.52) | TSHRIDO1NAAACHRM3LTA4H | |
| SCHEMBL134086 | 0.91 | IDO1 (0.61) | TSHRIDO1CHRM3MAOBAPP | |
| SCHEMBL4004770 | 0.89 | L3MBTL1 (0.58) | TSHRIDO1NAAACHRM3LTA4H | |
| SCHEMBL9342149 | 0.88 | IDO1 (0.58) | TSHRIDO1NAAACHRM3MAOB | |
| SCHEMBL21578433 | 0.88 | IDO1 (0.58) | TSHRIDO1NAAACHRM3MAOB | |
| SCHEMBL9342899 | 0.88 | IDO1 (0.58) | TSHRIDO1NAAACHRM3MAOB | |
| SCHEMBL1991359 | 0.88 | TSHR (0.78) | TSHRIDO1NAAALTA4HTDP1 | |
| SCHEMBL13643219 | 0.87 | L3MBTL1 (0.65) | TSHRIDO1LTA4HTDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1020445-B1 | FUSED PYRIDINE DERIVATIVES | EISAI R&D MAN CO LTD (JP) | 2008-08-13 | — | — | EP | disclosed |
| US-20040204421-A1 | Certain 1,3-disubstituted isoquinoline derivatives | EISAI CO., LTD. | 2004-10-14 | — | — | US | disclosed |
| US-6790844-B2 | MUSCLE RELAXANTS; ANTISEROTONINE AGENT | EISAI CO., LTD (JP) | 2004-09-14 | — | — | US | disclosed |
| US-20020013460-A1 | Condensed pyridine compound | EISAI CO., LTD | 2002-01-31 | — | — | US | disclosed |
| US-6340759-B1 | ANTISPASMODIC AGENTS | EISAI CO., LTD. (JP) | 2002-01-22 | — | — | US | disclosed |
| EP-1020445-A1 | FUSED PYRIDINE DERIVATIVES | Eisai Co., Ltd. (JP) | 2000-07-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013460-A1 | Condensed pyridine compound | MUSK, HTR1A, PAX3 | TSHR 1481/4885IDO1 1075/4885NAAA 1262/4885 |
| US-20040204421-A1 | Certain 1,3-disubstituted isoquinoline derivatives | MUSK, HTR1A, RYR1 | TSHR 962/4885IDO1 216/4885NAAA 2379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.